Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Positive Technologies board of directors recommends second part of 2022 dividend

4/6/23 POSI

Shareholders of Positive Technologies approved first part of the dividend for 2022

4/6/23 POSI

Sberbank launched a mortgage on commercial real estate for individuals

4/6/23 SBER

Board of Directors of RosDorBank recommended that dividends be paid for 2022

4/6/23 RDRB

Softline's Russian business will be transferred to management company Tatis Capital

4/6/23 SFTL

Ozon's turnover in 2022 increased by 86%

4/6/23 OZON

Ozon revenue in 2022 increased by 55.5%

4/6/23 OZON

Bank Uralsib reported for 2022 according to RAS

4/6/23 USBN

Positive Technologies reported for 2022 according to IFRS

4/6/23 POSI

Whoosh will equip scooters with a computer vision module

4/6/23 WUSH